{"protocolSection": {"identificationModule": {"nctId": "NCT00384865", "orgStudyIdInfo": {"id": "458"}, "secondaryIdInfos": [{"id": "R01HL082895-01", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01HL082895-01"}], "organization": {"fullName": "University of Pennsylvania", "class": "OTHER"}, "briefTitle": "A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension", "officialTitle": "A Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-09"}, "primaryCompletionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-09-30", "studyFirstSubmitQcDate": "2006-10-05", "studyFirstPostDateStruct": {"date": "2006-10-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-11-16", "resultsFirstSubmitQcDate": "2017-07-18", "resultsFirstPostDateStruct": {"date": "2017-07-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-07-18", "lastUpdatePostDateStruct": {"date": "2017-07-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Pennsylvania", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether aspirin and simvastatin are safe and effective for the treatment of pulmonary arterial hypertension (PAH).", "detailedDescription": "PAH is characterized by dyspnea, fatigue, and lower extremity edema as a result of heart failure. In PAH, in situ thrombosis may occur in the lungs, and pulmonary endothelial dysfunction is well-recognized. As aspirin inhibits platelet aggregation, there may be value in using aspirin to treat PAH. Simvastatin has beneficial effects on blood vessels in other types of cardiovascular disease. Therefore, simvastatin may similarly benefit patients with PAH.\n\nParticipants in this study will be randomly assigned to receive 6 months of daily placebo tablets, daily aspirin and daily placebo, daily simvastatin and daily placebo, or daily aspirin and daily simvastatin in a double-blind fashion. The study will compare the safety and efficacy of aspirin to placebo and simvastatin to placebo."}, "conditionsModule": {"conditions": ["Hypertension, Pulmonary"], "keywords": ["Pulmonary Arterial Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "FACTORIAL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 64, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aspirin 81 mg + Simvastatin 40 mg", "type": "ACTIVE_COMPARATOR", "description": "Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months\n\nAspirin: Aspirin 81 mg, taken orally, once a day for 6 months", "interventionNames": ["Drug: Simvastatin", "Drug: Aspirin"]}, {"label": "Aspirin 81 mg + Placebo", "type": "ACTIVE_COMPARATOR", "description": "Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months\n\nPlacebo taken orally, once a day for 6 months", "interventionNames": ["Drug: Aspirin", "Drug: Placebo"]}, {"label": "Placebo + Simvastatin 40 mg", "type": "ACTIVE_COMPARATOR", "description": "Placebo taken orally, once a day for 6 months\n\nSimvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months", "interventionNames": ["Drug: Simvastatin", "Drug: Placebo"]}, {"label": "Placebo + Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo taken orally, once a day for 6 months\n\nPlacebo taken orally, once a day for 6 months", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Simvastatin", "description": "Simvastatin 40 mg, taken orally, once a day for 6 months", "armGroupLabels": ["Aspirin 81 mg + Simvastatin 40 mg", "Placebo + Simvastatin 40 mg"], "otherNames": ["Zocor"]}, {"type": "DRUG", "name": "Aspirin", "description": "Aspirin 81 mg, taken orally, once a day for 6 months", "armGroupLabels": ["Aspirin 81 mg + Placebo", "Aspirin 81 mg + Simvastatin 40 mg"], "otherNames": ["acetylsalicylic acid"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo, taken orally, once a day for 6 months", "armGroupLabels": ["Aspirin 81 mg + Placebo", "Placebo + Placebo", "Placebo + Simvastatin 40 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Distance Walked in Six Minutes", "timeFrame": "Measured at 6 months"}], "secondaryOutcomes": [{"measure": "Time to Clinical Worsening Events (Number of Events)", "description": "Defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death.", "timeFrame": "Measured at 6 months"}, {"measure": "Adverse Events", "description": "Please refer to the Adverse Event Tables for specific information", "timeFrame": "Measured at 6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Mean pulmonary artery pressure greater than 25 mm Hg at rest with a pulmonary capillary wedge pressure less than 16 mm Hg\n* Diagnosis of PAH that is a) idiopathic, b) familial, or c) associated with collagen vascular disease, HIV infection, congenital systemic-to-pulmonary shunt, or former anorexigen use\n* Most recent pulmonary function tests showing FEV1/FVC ratio greater than 50% AND one of the following conditions: a) total lung capacity greater than 70% predicted, or b) total lung capacity between 60% and 70% of predicted value with no more than mild patchy interstitial lung disease on high resolution computerized tomography of the chest\n* Ability to perform six-minute walk testing without limitations in musculoskeletal function or coordination\n* Negative pregnancy test at screening visit for women of childbearing potential\n* If female, willing to use adequate form of birth control\n\nExclusion Criteria:\n\n* PAH related to other etiologies\n* Diagnosis of sickle cell disease\n* Clinically significant untreated sleep apnea, as diagnosed by polysomnography\n* Left-sided valvular disease (more than moderate mitral valve stenosis or insufficiency or aortic stenosis or insufficiency), pulmonary artery or valve stenosis, or ejection fraction less than 45% on echocardiography\n* Hospitalized or acutely ill\n* Kidney failure\n* Initiation of PAH therapy (prostacyclin analogues, endothelin \\[ET\\]-1 receptor antagonists, phosphodiesterase \\[PDE\\]-5 inhibitors) within 3 months of study entry\n* Allergy or hypersensitivity to aspirin or simvastatin\n* Absolute indication for aspirin or other anti-platelet therapy\n* Current treatment with statin therapy\n* Inability or unwillingness to avoid non-steroidal, anti-inflammatory medications for 6 months following study entry\n* Current or recent use or planned treatment with one of the following: amiodarone, cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, cimetidine, danazol, large quantities of grapefruit juice (more than 1 quart daily), verapamil, fibrates, or niacin\n* Peptic or duodenal ulcer diagnosed within 1 year of study entry\n* Gastrointestinal bleeding within 6 months prior of study entry\n* Bleeding diathesis\n* History of intracranial bleeding\n* Anemia (hematocrit less than 30%) at screening\n* International normalized ratio (INR) greater than 3.0 at screening\n* Severe thrombocytopenia (less than 75,000/L) at screening\n* Hepatic transaminases greater than twice the upper limit of normal at screening\n* Chronic liver disease (e.g., cirrhosis, chronic hepatitis) with portal hypertension\n* Current or recent (within 6 months of study entry) chronic heavy alcohol consumption\n* History of myositis\n* Creatine phosphokinase (CPK) greater than 1.5 times the upper limit of normal at screening\n* Abnormalities of the arm or hand or past radical mastectomy that might prevent brachial artery ultrasound\n* Pregnant or breastfeeding\n* Current use of another investigational drug for PAH\n* Received a lung transplant", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Steven M Kawut, MD, MS", "affiliation": "University of Pennsylvania", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "David J Lederer, MD, MS", "affiliation": "Columbia University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Reda E Girgis, MB, BCh", "affiliation": "Johns Hopkins University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Kari E Roberts, MD", "affiliation": "Tufts University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Johns Hopkins University", "city": "Baltimore", "state": "Maryland", "zip": "21205", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Tufts University School of Medicine", "city": "Boston", "state": "Massachusetts", "zip": "02110", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Columbia University", "city": "New York", "state": "New York", "zip": "10032", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}]}, "referencesModule": {"references": [{"pmid": "21593252", "type": "RESULT", "citation": "Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, Hill NS, Barr RG, Rosenzweig EB, Post W, Tracy RP, Palevsky HI, Hassoun PM, Girgis RE; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation. 2011 Jun 28;123(25):2985-93. doi: 10.1161/CIRCULATIONAHA.110.015693. Epub 2011 May 18."}, {"pmid": "26501464", "type": "DERIVED", "citation": "Al-Naamani N, Palevsky HI, Lederer DJ, Horn EM, Mathai SC, Roberts KE, Tracy RP, Hassoun PM, Girgis RE, Shimbo D, Post WS, Kawut SM; ASA-STAT Study Group. Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2016 Jan;13(1):25-30. doi: 10.1513/AnnalsATS.201508-543OC."}, {"pmid": "25615959", "type": "DERIVED", "citation": "Matura LA, Ventetuolo CE, Palevsky HI, Lederer DJ, Horn EM, Mathai SC, Pinder D, Archer-Chicko C, Bagiella E, Roberts KE, Tracy RP, Hassoun PM, Girgis RE, Kawut SM. Interleukin-6 and tumor necrosis factor-alpha are associated with quality of life-related symptoms in pulmonary arterial hypertension. Ann Am Thorac Soc. 2015 Mar;12(3):370-5. doi: 10.1513/AnnalsATS.201410-463OC."}, {"pmid": "21146637", "type": "DERIVED", "citation": "Kawut SM, Bagiella E, Shimbo D, Lederer DJ, Al-Naamani N, Roberts KE, Barr RG, Post W, Horn EM, Tracy R, Hassoun P, Girgis R; ASA-STAT Study Group. Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT. Contemp Clin Trials. 2011 Mar;32(2):280-7. doi: 10.1016/j.cct.2010.12.005. Epub 2010 Dec 10."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aspirin 81 mg + Simvastatin 40 mg", "description": "Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months\n\nAspirin: Aspirin 81 mg, taken orally, once a day for 6 months"}, {"id": "FG001", "title": "Aspirin 81 mg + Placebo", "description": "Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months\n\nPlacebo: Placebo, taken orally, once a day for 6 months"}, {"id": "FG002", "title": "Placebo + Simvastatin 40 mg", "description": "Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months\n\nPlacebo: Placebo, taken orally, once a day for 6 months"}, {"id": "FG003", "title": "Placebo + Placebo", "description": "Placebo: Placebo, taken orally, once a day for 6 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "16"}]}, {"type": "Completed Six Month Assessment", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "15"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "16"}, {"groupId": "FG003", "numSubjects": "16"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aspirin 81 mg + Simvastatin 40 mg", "description": "Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months\n\nAspirin: Aspirin 81 mg, taken orally, once a day for 6 months"}, {"id": "BG001", "title": "Aspirin 81 mg + Placebo", "description": "Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months\n\nPlacebo: Placebo, taken orally, once a day for 6 months"}, {"id": "BG002", "title": "Placebo + Simvastatin 40 mg", "description": "Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months\n\nPlacebo: Placebo, taken orally, once a day for 6 months"}, {"id": "BG003", "title": "Placebo + Placebo", "description": "Placebo: Placebo, taken orally, once a day for 6 months"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "64"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.6", "spread": "16.6"}, {"groupId": "BG001", "value": "56.75", "spread": "13.2"}, {"groupId": "BG002", "value": "58.6", "spread": "11.7"}, {"groupId": "BG003", "value": "63.5", "spread": "14.2"}, {"groupId": "BG004", "value": "59.6", "spread": "13.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "55"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "9"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "8"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "56"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "3"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "13"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "45"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "3"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "16"}, {"groupId": "BG003", "value": "16"}, {"groupId": "BG004", "value": "64"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Distance Walked in Six Minutes", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "meters", "timeFrame": "Measured at 6 months", "groups": [{"id": "OG000", "title": "Aspirin 81 mg", "description": "Aspirin 81 mg, taken orally, once a day for 6 months"}, {"id": "OG001", "title": "Aspirin Placebo", "description": "Placebo, taken orally, once a day for 6 months"}, {"id": "OG002", "title": "Simvastatin 40 mg", "description": "Simvastatin 40 mg, taken orally, once a day for 6 months"}, {"id": "OG003", "title": "Simvastatin Placebo", "description": "Placebo, taken orally, once a day for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "438.0", "lowerLimit": "415.9", "upperLimit": "460.1"}, {"groupId": "OG001", "value": "438.5", "lowerLimit": "419.2", "upperLimit": "457.8"}, {"groupId": "OG002", "value": "425.0", "lowerLimit": "400.2", "upperLimit": "449.9"}, {"groupId": "OG003", "value": "452.7", "lowerLimit": "431.9", "upperLimit": "473.4"}]}]}]}, {"type": "SECONDARY", "title": "Time to Clinical Worsening Events (Number of Events)", "description": "Defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events", "timeFrame": "Measured at 6 months", "groups": [{"id": "OG000", "title": "Aspirin 81 mg", "description": "Aspirin 81 mg, taken orally, once a day for 6 months"}, {"id": "OG001", "title": "Aspirin Placebo", "description": "Placebo, taken orally, once a day for 6 months"}, {"id": "OG002", "title": "Simvastatin 40 mg", "description": "Simvastatin 40 mg, taken orally, once a day for 6 months"}, {"id": "OG003", "title": "Simvastatin Placebo", "description": "Placebo, taken orally, once a day for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "4"}, {"groupId": "OG003", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Adverse Events", "description": "Please refer to the Adverse Event Tables for specific information", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events", "timeFrame": "Measured at 6 months", "groups": [{"id": "OG000", "title": "Aspirin 81 mg", "description": "Aspirin 81 mg, taken orally, once a day for 6 months"}, {"id": "OG001", "title": "Aspirin Placebo", "description": "Placebo, taken orally, once a day for 6 months"}, {"id": "OG002", "title": "Simvastatin 40 mg", "description": "Simvastatin 40 mg, taken orally, once a day for 6 months"}, {"id": "OG003", "title": "Simvastatin Placebo", "description": "Placebo, taken orally, once a day for 6 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "32"}, {"groupId": "OG003", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "59"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "66"}, {"groupId": "OG003", "value": "58"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse event data was collected for each subject from screening through 6 months after enrollment/randomization", "eventGroups": [{"id": "EG000", "title": "Aspirin 81 mg", "description": "Aspirin 81 mg, taken orally, once a day for 6 months", "seriousNumAffected": 4, "seriousNumAtRisk": 32, "otherNumAffected": 32, "otherNumAtRisk": 32}, {"id": "EG001", "title": "Aspirin Placebo", "description": "Placebo, taken orally, once a day for 6 months", "seriousNumAffected": 1, "seriousNumAtRisk": 33, "otherNumAffected": 33, "otherNumAtRisk": 33}, {"id": "EG002", "title": "Simvastatin 40 mg", "description": "Simvastatin 40 mg, taken orally, once a day for 6 months", "seriousNumAffected": 0, "seriousNumAtRisk": 32, "otherNumAffected": 32, "otherNumAtRisk": 32}, {"id": "EG003", "title": "Simvastatin Placebo", "description": "Placebo, taken orally, once a day for 6 months", "seriousNumAffected": 0, "seriousNumAtRisk": 33, "otherNumAffected": 33, "otherNumAtRisk": 33}], "seriousEvents": [{"term": "Major Bleeding Episode", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 33}]}], "otherEvents": [{"term": "Upper Respiratory Infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 12, "numAffected": 12, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 9, "numAffected": 9, "numAtRisk": 33}]}, {"term": "Bruising", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 10, "numAffected": 10, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 6, "numAffected": 6, "numAtRisk": 33}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 5, "numAffected": 5, "numAtRisk": 33}]}, {"term": "Headache", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 33}]}, {"term": "Other Infections", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 33}]}, {"term": "Dyspnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 33}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 33}]}, {"term": "Chest Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}]}, {"term": "Increased Transaminases", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 33}]}, {"term": "Insomnia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 33}]}, {"term": "Minor Bleeding Episode", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 32}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 33}, {"groupId": "EG002", "numEvents": 14, "numAffected": 14, "numAtRisk": 32}, {"groupId": "EG003", "numEvents": 13, "numAffected": 13, "numAtRisk": 33}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "* The primary end point that should be used in early-stage clinical trials in PAH is uncertain.\n* We did not include invasive hemodynamic end points.\n* Early termination led to missing data for those active subjects in the trial at termination (n16)."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Steven Kawut", "organization": "Penn", "email": "kawut@upenn.edu", "phone": "215-573-0258"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000081029", "term": "Pulmonary Arterial Hypertension"}, {"id": "D000006976", "term": "Hypertension, Pulmonary"}, {"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}], "browseLeaves": [{"id": "M2261", "name": "Pulmonary Arterial Hypertension", "asFound": "Pulmonary Arterial Hypertension", "relevance": "HIGH"}, {"id": "M10027", "name": "Hypertension, Pulmonary", "asFound": "Hypertension, Pulmonary", "relevance": "HIGH"}, {"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "T4807", "name": "Pulmonary Arterial Hypertension", "asFound": "Pulmonary Arterial Hypertension", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001241", "term": "Aspirin"}, {"id": "D000019821", "term": "Simvastatin"}], "ancestors": [{"id": "D000000894", "term": "Anti-Inflammatory Agents, Non-Steroidal"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000018501", "term": "Antirheumatic Agents"}, {"id": "D000005343", "term": "Fibrinolytic Agents"}, {"id": "D000050299", "term": "Fibrin Modulating Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000010975", "term": "Platelet Aggregation Inhibitors"}, {"id": "D000016861", "term": "Cyclooxygenase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000058633", "term": "Antipyretics"}, {"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}], "browseLeaves": [{"id": "M4548", "name": "Aspirin", "asFound": "Knee Arthroplasty", "relevance": "HIGH"}, {"id": "M21713", "name": "Simvastatin", "asFound": "Virus", "relevance": "HIGH"}, {"id": "M4218", "name": "Anti-Inflammatory Agents, Non-Steroidal", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M20604", "name": "Antirheumatic Agents", "relevance": "LOW"}, {"id": "M8473", "name": "Fibrinolytic Agents", "relevance": "LOW"}, {"id": "M13865", "name": "Platelet Aggregation Inhibitors", "relevance": "LOW"}, {"id": "M19209", "name": "Cyclooxygenase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M29176", "name": "Antipyretics", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Antipy", "name": "Antipyretics"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "FiAg", "name": "Fibrinolytic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "PlAggInh", "name": "Platelet Aggregation Inhibitors"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Lipd", "name": "Lipid Regulating Agents"}]}}, "hasResults": true}